Replies to post #104113 on Avid Bioservices Inc (CDMO)

[DewDiligence]

I believe it is very positive, especially when considering the statements made by some on this board that the Co. would never again mention the 2nd-line NSCLC trial, and instead move on to "other things" to divert attention and hope the 2nd-line trial would be forgotten.

The grand scheme has not changed: Talk about other programs as much as possible and, eventually, investors will stop expecting to be updated on the second-line lung trial. Management is very confident that its retail shareholder base will fall for the ruse.